Interplay of miRNA-146a and miRNA-126 in Chronic Periodontitis Patients With Coronary Artery Disease

Meenakshi Ammal Dental College and Hospital

Status: Completed

Conditions: Coronary Artery Disease; miRNA; Chronic Periodontitis

Study type: Observational

Funder types: Other

Identifiers

NCT04583085

MADC/IRB-XXVI/2018/415

Details and patient eligibility

About

The role of micro-RNAs in chronic periodontitis associated with CAD is still in an incipient stage needs to be explored further. The investigators attempt to quantify and compare the levels of micro-RNA 146a and micro-RNA 126 in subgingival as well as coronary plaque samples obtained from patients diagnosed with chronic periodontitis with and without coronary artery disease.

Full description

The role of micro-RNAs in chronic periodontitis associated with CAD is still in an incipient stage needs to be explored further. The investigators attempt to quantify and compare the levels of micro-RNA 146a and micro-RNA 126 in subgingival as well as coronary plaque samples obtained from patients diagnosed with chronic periodontitis with and without coronary artery disease.

Seventy-five participants were selected and grouped into 3 categories; 25 patients diagnosed with chronic periodontitis and coronary artery disease: CP + CAD group; 25 patients diagnosed with chronic periodontitis alone: CP group; and 25 systemically and periodontally healthy controls (HP). Demographic variables, periodontal parameters, cardiac parameters, blood pressure were obtained. miRNA-146a and miRNA126 levels were assessed in subgingival plaque (SP) samples from all the three groups. Within CP+CAD group, SP samples of CP+CADa were compared with coronary plaques samples (CP) of CP+CADb while the patient underwent CABG.

Enrollment: 75 patients

Sex: Male

Ages: 30 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients volunteering for the investigation.
• Patients between the age group of 30-70 years
• Presence of ≥ 15 natural teeth.

Exclusion criteria

• Patients associated with systemic diseases such as lung disorders, renal disease, liver disease, type I, type II-diabetes mellitus, HIV infection, rheumatoid arthritis, allergy or any malignancy.
• Under treatment with antibiotics, immunosuppressive drugs such as corticosteroids, within 6 months.
• Pregnant women and female patients were excluded because of the altered oral flora due to hormonal changes
• Smoking and other tobacco usage habits
• Patients who underwent periodontal treatment within 6 months.

Trial design

75 participants in 3 patient groups

CP + CHD group

Description:

This was further divided into CP + CHDa (Subgingival plaque) and CP + CHDb (Coronary plaque) based on the nature of plaque collected.

CP group

Description:

25 patients with chronic periodontitis who were systemically healthy were selected

HP group

Description:

25 patients who were systemically and periodontally healthy, were considered as HP group.